| Follow us on Twitter |
(Amherst, NH) – The introduction of new technologies and products for the treatment of acute and chronic wounds is providing caregivers with a set of powerful options that will have a profound effect on the field of wound management. These new treatment tools, which mimic the body’s natural physiology and/or regenerative pathways, include tissue-engineered skin substitutes, regeneration matrices, and biologically active cellular therapies.
These emerging products will be competing in a worldwide market worth billions, and in which improvements in quality-of-life and treatment outcomes continue to be top healthcare industry initiatives. As further data on patient outcomes becomes available, the number of approved indications as well as third party payer acceptance for bioengineered wound care products and therapies will increase, driving growth to significant levels beginning in the latter part of the decade.
Bioengineered Wound Care, a recently released report, analyzes emerging therapeutics, market participants, and key regulatory and technology factors influencing this market and driving acceptance of these next-generation wound care technologies. It is available from Greystone Associates by visiting
http://www.greystoneassociates.org/Bioengineered_Wound_Care.htm
More information is also available at www.greystoneassociates.org .
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
Contact:
Mark Smith
Voice: 603-595-4340
Fax: 603-804-0466
www.greystoneassociates.org
Source: Greystone Associates
Posted August 7th, 2007 by mksmith
